Targets › IL6
13 programs from 13 companies in 20 trials: 12 Phase 2, 4 Phase 3, 3 Phase 1, 1 Phase 4; Oncology, Cardiovascular, Immunology; next expected readout Dec 2026.
Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). (UniProt, P05231)
Open in Phaseline: the race on IL6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Alaa Ashraf Muhammad Helal | Diacerein IL-6 inhibitor | IL6 | Phase 4 | Psoriasis Vulgaris | Feb 2027 |
| Novo Nordisk | Ziltivekimab Interleukin-6 inhibitor; Interleukin-6 binding agent | IL6 | Phase 3 | Heart Failure; Cardiovascular Risk; Myocardial Infarction | Jan 2027 |
| R-Pharm | Olokizumab Interleukin-6 inhibitor | IL6 | Phase 3 | Polymyalgia Rheumatica; Lung Diseases, Interstitial; Juvenile Idiopathic Arthritis | Apr 2027 |
| Yuanquan Yang | Siltuximab Interleukin-6 antagonist | IL6 | Phase 2 | Advanced Malignant Solid Neoplasm | Dec 2026 |
| Sir Run Run Shaw Hospital | Icaritin Downregulates TNF-α, IL-6, and PD-L1 expression; reduces MDSC proportion to modulate tumor | TNF, IL6, PDCD1LG1 | Phase 2 | Advanced Pancreatic Ductal Adenocarcinoma | Apr 2027 |
| Eli Lilly | Clazakizumab (LY5724886) Interleukin-6 inhibitor | IL6 | Phase 2 | Atherosclerosis | May 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | Siltuximab Interleukin-6 antagonist | IL6 | Phase 2 | CRS - Cytokine Release Syndrome | Aug 2027 |
| CSL Behring | Clazakizumab (CSL300) Interleukin-6 inhibitor | IL6 | Phase 2 | End Stage Kidney Disease; End Stage Kidney Disease (ESKD); COVID-19 Infection | Aug 2027 |
| Tourmaline Bio, Inc., a Novartis Company | Pacibekitug (TOUR006) Interleukin-6 inhibitor | IL6 | Phase 2 | Thyroid Eye Disease | Sep 2027 |
| Memorial Sloan Kettering Cancer Center | Siltuximab Interleukin-6 antagonist | IL6 | Phase 2 | Multiple Myeloma | Oct 2027 |
| Massachusetts General Hospital | Siltuximab Interleukin-6 antagonist | IL6 | Phase 2 | Schwannomatosis | Nov 2027 |
| Washington University School of Medicine | Siltuximab Interleukin-6 antagonist | IL6 | Phase 1 | Antibody Mediated Rejection of Lung Transplant | Dec 2027 |
| Taylor Brooks | Siltuximab Interleukin-6 antagonist | IL6 | Phase 1 | Non-Hodgkin Lymphoma | Sep 2028 |
Multiple Myeloma (2) Antibody Mediated Rejection of Lung Transplant (1) Heart Failure (1) Cardiovascular Risk (1) Myocardial Infarction (1) End Stage Kidney Disease (1) End Stage Kidney Disease (ESKD) (1) COVID-19 Infection (1) Atherosclerosis (1) CRS - Cytokine Release Syndrome (1) Advanced Pancreatic Ductal Adenocarcinoma (1) Polymyalgia Rheumatica (1)
antibody (8), small molecule (4), mixed (1)
Memorial Sloan Kettering Cancer Center (1) Washington University School of Medicine (1) Novo Nordisk (1) CSL Behring (1) Eli Lilly (1) Institute of Hematology & Blood Diseases Hospital, China (1) Sir Run Run Shaw Hospital (1) R-Pharm (1) Tourmaline Bio, Inc., a Novartis Company (1) Alaa Ashraf Muhammad Helal (1) Yuanquan Yang (1) Massachusetts General Hospital (1) Taylor Brooks (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.